Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-12-14

Clinical Trial Update: Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia [Phase 4]

View source ↗

Summary

A Phase 4 randomized double-blind trial comparing aripiprazole and risperidone in schizophrenia was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ARIPIPRAZOLE (Aripiprazole)
  • RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Kettering Health Network | Conditions: Schizophrenia | Phase 4 | Status: TERMINATED | Results posted: 2018-12-14